Taurolidine in the prevention and therapy of lung metastases

Hoksch, Beatrix; Rufer, Benjamin; Gazdhar, Amiq; Bilici, Murat; Beshay, Morris; Gugger, Matthias; Schmid, Ralph A.

doi:10.1016/j.ejcts.2009.04.065

Cited by 6 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, a lot of researches through light on the use of taurilidine as antineoplastic drug in human bladder carcinoma [49] gastro-intestinal cancer [50] to prevent the development of lung metastasis [51], and it may offer additional therapeutic option in patient with colon adenocarcinoma [51], as a useful modulator to enhance the therapeutic index of some antitumor agents [16], in the treatment of oesophageal cancer [14], in treatment of malignant mesothelioma [52] and as a biomarker in non-muscle invasive bladder cancer [53]. In conclusion and based on the present study we can strongly suggest the assessment of taurine level in sera of patients with high risk of breast cancer and in the early diagnosis of any malignant changes in the breast.…”

Section: Discussionmentioning

confidence: 99%

Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients

et al. 2011

View full text Add to dashboard Cite

show abstract

“…[44–4648–53] or i.v. application[54–58] of TRD. Recently, i.p.-applicated TRD has been evaluated in patients undergoing major surgery for CRC.…”

Section: Discussionmentioning

confidence: 99%

Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium-induced colitis-associated carcinogenesis in mice

Chromik¹,

Huss

Osseili

et al. 2010

J Carcinog

View full text Add to dashboard Cite

Background:New chemopreventive strategies for ulcerative colitis (UC)-associated dysplasia and cancer have to be evaluated. Taurolidine (TRD) has anti-inflammatory, anti-proliferative and anti-neoplastic properties with almost absent toxicity. The aim of the study was to determine whether TRD decreases dysplasia in the well-characterized Dextran Sulfate Sodium – Azoxymethane (DSS-AOM) animal model for UC-associated carcinogenesis.Material and Methods:The DSS-AOM model of carcinogenesis was induced in female inbred C57BL/6 mice. Half of the mice were treated with TRD, the other served as control. After 100 days macroscopic, histological and immunhistochemical (β-Catenin, E-Cadherin, SOX9, Ki-67, Cyclin-D1) examination of the colon was performed.Results:Incidence, multiplicity, grading and growth pattern of adenomas did not differ significantly between TRD and control group. In all animals, inflammatory changes were absent. Immunhistochemistry revealed increased expression of Ki-67, β-catenin, SOX9 and Cyclin-D1 in adenomas compared to normal mucosa – without significant difference between TRD and control treatment.Conclusion:Oral administration of TRD has no impact on DSS-induced colitis-associated carcinogenesis. However, SOX9 and Cyclin-D1 representing key members of the Wnt pathway have not yet been described in the DSS-AOM model of carcinogenesis – underlining the importance of this oncogenic pathway in this setting.

show abstract

“…Therefore, taurolidine was used in inflammatory experimental and clinical studies as prophylaxis against catheter associated infections [ 14 – 17 ]. Additionally, taurolidine was investigated in experimental oncology and showed promising results in tumor therapy [ 18 – 27 ]. Several mechanisms were discussed, such as direct apoptosis of the tumor cells [ 5 ] or indirectly via inhibition of NF-kappaB and consecutive inhibition of anti-apoptotic regulator leading to cell death [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Short-term treatment with taurolidine is associated with liver injury

Fahrner

Möller

Press

et al. 2017

BMC Pharmacol Toxicol

View full text Add to dashboard Cite

BackgroundTaurolidine has been used for peritonitis, oncological and catheter-lock treatment because of its anti-inflammatory properties. It has been suggested that taurolidine has no severe side-effects, but after long-term use morphological and functional changes of the liver were reported. The aim of this study was to investigate the effect of short-term use of taurolidine on the liver.MethodsIn HepaRG cell cultures and on a novel liver biochip dose-dependent effects of taurolidine treatment on hepatocyte adherence and cell viability was investigated. Furthermore, liver enzymes and interleukin- (IL-) 6 were measured in supernatants. Male rats were treated with low- or high-dose taurolidine, respectively, and compared to controls with physiological saline solution administration regarding blood serum parameters and histology.ResultsIn HepaRG cell cultures, hepatocyte adherence was significantly decreased, cell death and cleaved caspase-3 were significantly increased after administration of taurolidine in a dose-dependent manner. High-dose application of taurolidine led to elevated liver enzymes and IL-6 secretion in hepatic organoid. After 24 h a significant increase of serum GLDH and ASAT was observed in rats treated with high-dose taurolidine treatment.ConclusionsOur results suggest that taurolidine caused liver injury after short-term use in in vitro and in vivo models probably due to direct toxic effects on hepatocytes. Therefore, the taurolidine dose should be titrated in further investigations regarding liver injury and inflammation.Electronic supplementary materialThe online version of this article (doi:10.1186/s40360-017-0168-z) contains supplementary material, which is available to authorized users.

show abstract

Taurolidine in the prevention and therapy of lung metastases

Abstract: The application of taurolidine tends to prevent the development of lung metastases. Furthermore, taurolidine seems to reduce established lung metastases in this in vivo model. Taurolidine may offer additional therapeutic options in patients with colon adenocarcinoma.

Cited by 6 publications

References 17 publications

Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients

Taurine: a novel tumor marker for enhanced detection of breast cancer among female patients

Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium-induced colitis-associated carcinogenesis in mice

Short-term treatment with taurolidine is associated with liver injury

Contact Info

Product

Resources

About